Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis. (Q54460498)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis. (English)

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

0 references

8

object named as

Josef S Smolen

1 reference

Europe PubMed Central

30 May 2018

author name string

Nikolaus B Binder

1

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

Antonia Puchner

2

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

Birgit Niederreiter

3

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

Silvia Hayer

4

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

Harald Leiss

5

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

Stephan Blüml

6

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

Roman Kreindl

7

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

Kurt Redlich

9

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

publication date

1 March 2013

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

Arthritis and Rheumatism

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

65

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

3

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

608-617

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Osteoclasts are essential for TNF-alpha-mediated joint destruction

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Bone remodeling in rheumatic disease: a question of balance

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Bone resorption by osteoclasts

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor.

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab.

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with c

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1.

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

CD44 is a determinant of inflammatory bone loss

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression.

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Role of cytokines in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Rheumatic diseases: the effects of inflammation on bone

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

TNF-induced structural joint damage is mediated by IL-1.

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: Results from the trial of etanercept and methotrexate with radiographic and patient outcomes

1 reference

https://api.crossref.org/works/10.1002%2FART.37797

21 January 2018

Identifiers

10.1002/ART.37797

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23280418

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54460498&oldid=1002717907"